NCT03427671 - OCL 500 Treatment of Women With Symptomatic Uterine Fibroids | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

September 3, 2019

Study Completion Date

September 3, 2019

Conditions

Uterine FibroidMyomaLeiomyoma

Interventions

DEVICE

Occlusin 500 Microspheres

Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.

Trial Locations (1)

T6G 2B7

University of Alberta Hospital, Edmonton